The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Social media users backed the groom in the viral post, with one saying "it's wild that she thinks she can just show up." ...

Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population. These preliminary results are being presented in a late-breaking poster at the ...